Neurocrine Biosciences competitors

Zippia score 4.7

Neurocrine Biosciences main competitors are Exelixis, Gilead Sciences, and Halozyme.

Competitor Summary. See how Neurocrine Biosciences compares to its main competitors:

Merck has the most employees (74,000).
Employees at Exelixis earn more than most of the competitors, with an average yearly salary of $108,978.
The oldest company is Merck, founded in 1891.

Work at Neurocrine Biosciences?

Share your experience

Neurocrine Biosciences vs competitors

Company	Founding date	Zippia score	Headquarters	# of Locations	Revenue	Employees
Neurocrine Biosciences	1992	4.7	San Diego, CA	1	$2.4B	400
Regeneron	1988	4.9	Tarrytown, NY	7	$14.2B	9,123
Amgen	1980	4.8	Thousand Oaks, CA	9	$33.4B	22,000
Seagen	1997	4.7	Bothell, WA	3	$2.0B	900
Gilead Sciences	1987	4.5	Foster City, CA	9	$28.8B	11,800
Merck	1891	4.6	Kenilworth, NJ	31	$64.2B	74,000
Sanofi Genzyme	1981	4.8	Cambridge, MA	1	$4.6B	12,000
Human Genome Sciences	1992	4.9	Rockville, MD	1	$131.0M	1,000
Hospira	2004	4.8	Lake Forest, IL	1	$4.5B	19,000
Halozyme	1998	4.8	San Diego, CA	1	$1.0B	136
Aeras	2003	4.8	Rockville, MD	1	$39.3M	72
Exelixis	1994	4.9	Alameda, CA	1	$2.2B	484
Senomyx	1998	4.3	San Diego, CA	1	$26.4M	56

Rate Neurocrine Biosciences' competitiveness in the market.

Neurocrine Biosciences salaries vs competitors

Among Neurocrine Biosciences competitors, employees at Exelixis earn the most with an average yearly salary of $108,978.

Compare Neurocrine Biosciences salaries vs competitors

Company	Average salary	Hourly salary	Salary score
Neurocrine Biosciences	$78,232	$37.61	-
Regeneron	$85,589	$41.15	-
Amgen	$93,349	$44.88	-
Seagen	$85,008	$40.87	-
Gilead Sciences	$99,828	$47.99	-
Merck	$90,328	$43.43	-

Compare Neurocrine Biosciences job title salaries vs competitors

Company	Highest salary	Hourly salary
Neurocrine Biosciences	$57,933	$27.85
Regeneron	$67,735	$32.56
Sanofi Genzyme	$67,563	$32.48
Merck	$67,476	$32.44
Gilead Sciences	$67,379	$32.39
Amgen	$67,033	$32.23
Hospira	$66,429	$31.94
Halozyme	$65,054	$31.28
Human Genome Sciences	$60,731	$29.20
Seagen	$59,356	$28.54
Aeras	$56,380	$27.11
Exelixis	$54,623	$26.26
Senomyx	$51,724	$24.87

Do you work at Neurocrine Biosciences?

Is Neurocrine Biosciences able to compete effectively with similar companies?

Neurocrine Biosciences jobs

Neurocrine Biosciences demographics vs competitors

Compare gender at Neurocrine Biosciences vs competitors

Job title	Male	Female
Merck	54%	46%
Regeneron	54%	46%
Gilead Sciences	56%	44%
Amgen	57%	43%
Neurocrine Biosciences	59%	41%
Senomyx	68%	32%

Male

Female

100%

75%

50%

25%

Senomyx

Neurocrine Biosciences

25%

50%

75%

100%

Compare race at Neurocrine Biosciences vs competitors

Company	White	Hispanic or Latino	Black or African American	Asian	Unknown	Diversity score
Neurocrine Biosciences	55%	22%	9%	9%	5%	8.9
Amgen	49%	24%	7%	15%	5%	9.7
Gilead Sciences	44%	20%	8%	23%	6%	9.8
Merck	56%	16%	10%	14%	4%	9.8
Regeneron	54%	15%	10%	17%	4%	9.8
Senomyx	40%	27%	6%	22%	4%	7.1

Neurocrine Biosciences revenue vs competitors

Neurocrine Biosciences revenue is $2.4B. Among it's competitors, the company with the highest revenue is Merck, $64.2B . The company with the lowest revenue is Senomyx, $26.4M.

Neurocrine Biosciences and similar companies CEOs

CEOBio

Robert A. Bradway

Amgen

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Michael M. Morrissey Ph.d

Exelixis

Michael Morrissey is a President/CEO at EXELIXIS, INC.; Board Member at EXELIXIS, INC.; and Board Member at XW LABORATORIES INC and is based in Danville, California. He has experience at Schering AG and has worked as VP:Discovery Research at Berlex Biosciences; Senior Scientist at Novartis; and Senior VP:Discovery at EXELIXIS, INC.. Michael studied at Harvard University and University of Wisconsin Oshkosh.

Daniel O’Day

Gilead Sciences

Robert M. Davis

Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Roger D. Dansey

Seagen

John Poyhonen

Senomyx

Paul Hudson

Sanofi Genzyme

Andrew Witty

Human Genome Sciences